Gefitinib (BioDeep_00000601005)
代谢物信息卡片
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
化学式: C22H24ClFN4O3 (446.1521)
中文名称: 吉非替尼 (ZD1839)
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI: InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:49668
- KEGGdrug: D01977
- PubChem: 123631
- Metlin: METLIN45475
- DrugBank: DB00317
- ChEMBL: CHEMBL939
- MeSH: Gefitinib
- CAS: 184475-35-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Zishun Guo, Xin Zhang, Dingtao Yang, Zhuozheng Hu, Jiajun Wu, Weijun Zhou, Shuoming Wu, Wenxiong Zhang. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.
Scientific reports.
2024 05; 14(1):10348. doi:
10.1038/s41598-024-61175-3. [PMID: 38710798] - Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2024 Apr; 1237(?):124100. doi:
10.1016/j.jchromb.2024.124100. [PMID: 38547701] - Lei Zhang, Chuncao Xu, Junyuan Huang, Shiqin Jiang, Zhiyan Qin, Lin Cao, Guoyao Tan, Zhongxiang Zhao, Min Huang, Jing Jin. Tanshinone IIA reverses gefitinib resistance in EGFR-mutant lung cancer via inhibition of SREBP1-mediated lipogenesis.
Phytotherapy research : PTR.
2024 Mar; 38(3):1574-1588. doi:
10.1002/ptr.8130. [PMID: 38282115] - Changju Ma, Xin Zhang, Xiaomin Mo, Yaya Yu, Zhenzhen Xiao, Jingjing Wu, Lina Ding, Chenjing Lei, Yanjuan Zhu, Haibo Zhang. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2024 Jan; 125(?):155351. doi:
10.1016/j.phymed.2024.155351. [PMID: 38232540] - Xin-Yi Ai, Xue-Feng Hou, Nian-Ping Feng. [Combination of shikonin and gefitinib reverses drug resistance in human non-small cell lung cancer and its mechanism].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.
2024 Jan; 49(1):175-184. doi:
10.19540/j.cnki.cjcmm.20230810.401. [PMID: 38403350] - Yalei Wang, Shuo Cheng, Huawei Zhang, Yali Zhang, Chengcheng Ding, Tiantian Peng, Weihang Chen, Ke Yang, Jiani Zhang, Yan Tan, Xu Wang, Zhaoheng Liu, Peng Wei, Miao Jiang, Qian Hua. Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model.
Recent patents on anti-cancer drug discovery.
2024; 19(3):308-315. doi:
10.2174/1574892818666230727143750. [PMID: 37723963] - Guibin Pang, Siqi Wei, Jian Zhao, Fu-Jun Wang. Improving nanochemoimmunotherapy efficacy by boosting "eat-me" signaling and downregulating "don't-eat-me" signaling with Ganoderma lucidum polysaccharide-based drug delivery.
Journal of materials chemistry. B.
2023 12; 11(48):11562-11577. doi:
10.1039/d3tb02118a. [PMID: 37982298] - Abdelrahman Y Sherif, Gamaleldin I Harisa, Ahmad A Shahba, Fahd A Nasr, Ehab I Taha, Ali S Alqahtani. Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach.
Drug development research.
2023 11; 84(7):1453-1467. doi:
10.1002/ddr.22097. [PMID: 37519092] - Yaya Yu, Zhenzhen Xiao, Chenjing Lei, Changju Ma, Lina Ding, Qing Tang, Yihan He, Yadong Chen, Xuesong Chang, Yanjuan Zhu, Haibo Zhang. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
BMC cancer.
2023 Aug; 23(1):732. doi:
10.1186/s12885-023-11243-0. [PMID: 37553597] - Pankaj Kumar, Bharti Mangla, Shamama Javed, Waquar Ahsan, Geeta Aggarwal. Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.
Nanomedicine (London, England).
2023 08; 18(18):1139-1160. doi:
10.2217/nnm-2023-0107. [PMID: 37665053] - Qing Tang, Mengfei Xu, Shunqin Long, Yaya Yu, Changju Ma, Rui Wang, Jing Li, Xi Wang, Fang Fang, Ling Han, Wanyin Wu, Sumei Wang. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Journal of ethnopharmacology.
2023 Jun; ?(?):116646. doi:
10.1016/j.jep.2023.116646. [PMID: 37269912] - Qiumei Fan, Xiaowei Liang, Zhipeng Xu, Siyuan Li, Shan Han, Yuntian Xiao, Qiongming Xu, Renyikun Yuan, Shilin Yang, Hongwei Gao. Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2023 May; 116(?):154884. doi:
10.1016/j.phymed.2023.154884. [PMID: 37209605] - Cai-Zhi Yang, Wei Guo, Yi-Fan Wang, Lei-Hao Hu, Jing Wang, Jia-Min Luo, Xiao-Hui Yao, Shan Liu, Lan-Ting Tao, Ling-Ling Sun, Li-Zhu Lin. Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway.
Journal of ethnopharmacology.
2023 May; 314(?):116566. doi:
10.1016/j.jep.2023.116566. [PMID: 37169317] - Qing Tang, Qichun Zhou, Jing Li, Xiaobing Yang, Rui Wang, Xi Wang, Mengfei Xu, Ling Han, Wanyin Wu, Sumei Wang. Solamargine enhanced gefitinib anti-tumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
Carcinogenesis.
2023 May; ?(?):. doi:
10.1093/carcin/bgad028. [PMID: 37144780] - Hongyan Lin, Hongwei Han, Minkai Yang, Zhongling Wen, Qingqing Chen, Yudi Ma, Xuan Wang, Changyi Wang, Tongming Yin, Xiaoming Wang, Guihua Lu, Hongyuan Chen, Jinliang Qi, Yonghua Yang. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
European journal of medicinal chemistry.
2023 Mar; 249(?):115166. doi:
10.1016/j.ejmech.2023.115166. [PMID: 36731272] - Jing-Qiang Huang, Ling-Xin Duan, Qiu-Yu Liu, He-Feng Li, Ao-Ping Hu, Jun-Wei Song, Chuxuan Lin, Bingsheng Huang, Da Yao, Bin Peng, Yehong Sun, Yuxin Wen, Lin Yang, Xingzhi Xu, Li-Yun Gong. Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer.
Oncogene.
2023 Mar; ?(?):. doi:
10.1038/s41388-023-02645-2. [PMID: 36869126] - Jiabin Zhou, Yuhan Liu, Jun Chen, Nanxiang Xiong, Dongye Yi. Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway.
Drug development research.
2023 Feb; ?(?):. doi:
10.1002/ddr.22048. [PMID: 36852868] - Gamaleldin I Harisa, Abdelrahman Y Sherif, Fars K Alanazi, Essam A Ali, Gamal A Omran, Fahd A Nasr, Sabry M Attia, Ali S Alqahtani. TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies.
Colloids and surfaces. B, Biointerfaces.
2023 Jan; 223(?):113148. doi:
10.1016/j.colsurfb.2023.113148. [PMID: 36706479] - Jin-Guo Wang, Da-Lei Li, Rong Fan, Meng-Jun Yan. Zerumbone combined with gefitinib alleviates lung cancer cell growth through the AKT/STAT3/SLC7A11 axis.
Neoplasma.
2023 Jan; ?(?):. doi:
10.4149/neo_2022_220418n423. [PMID: 36637083] - Abdelrahman Y Sherif, Gamaleldin I Harisa, Ahmad A Shahba, Fars K Alanazi, Wajhul Qamar. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.
Molecules (Basel, Switzerland).
2023 Jan; 28(1):. doi:
10.3390/molecules28010448. [PMID: 36615641] - Payal Deepak, Praveen Kumar, Prashant Pandey, Dilip Kumar Arya, Shweta Jaiswal, Anand Kumar, Archana Bharti Sonkar, Daoud Ali, Saud Alarifi, Mohankumar Ramar, P S Rajinikanth. Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma.
International journal of nanomedicine.
2023; 18(?):7021-7046. doi:
10.2147/ijn.s438307. [PMID: 38046236] - Xiaomin Yang, Hongyan Jiang, Jiang Ning, Shufen Zhang, Ying Cai, Liang Wang, Jinsong Yang, Guodong Xu, Wei Chen, Jianfei Wang. Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition.
International journal of immunopathology and pharmacology.
2023 Jan; 37(?):3946320231210737. doi:
10.1177/03946320231210737. [PMID: 37890097] - Jisong Zhang, Li Xu, Huihui Hu, Enguo Chen. The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer.
Drug delivery.
2022 Dec; 29(1):466-477. doi:
10.1080/10717544.2022.2032872. [PMID: 35147070] - P Sathishbabu, Umme Hani, C Shakeela, P R Hemanth Vikram, Mohammed Ghazwani, Riyaz Ali M Osmani, B M Gurupadayya, D V Gowda. A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Dec; 1212(?):123483. doi:
10.1016/j.jchromb.2022.123483. [PMID: 36279777] - Huihui Guo, Xilin Zhang, Shangzhi Xie, Tianwei Chen, Dong Xie, Ying Cai, Dawei Cui, Liang Wang, Wei Chen, Xiang Wang. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
International journal of oncology.
2022 Dec; 61(6):. doi:
10.3892/ijo.2022.5436. [PMID: 36205136] - Dai Cao, Die Chen, Jiang-Nan Xia, Wen-Yan Wang, Guo-Yuan Zhu, Li-Wen Chen, Chuantao Zhang, Bo Tan, Hui Li, Ying-Wei Li. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Nov; 155(?):113705. doi:
10.1016/j.biopha.2022.113705. [PMID: 36271541] - Jun Sheng, Leyi Liu, Ting Dong, Xiang Wu. Circ_SETD3 regulates gefitinib sensitivity and tumor progression by miR-873-5p-dependent regulation of APPBP2 in non-small cell lung cancer.
Journal of chemotherapy (Florence, Italy).
2022 Oct; 34(6):401-413. doi:
10.1080/1120009x.2021.2009991. [PMID: 34861803] - Ya-Bian Luo, Yan-Yao Hou, Zhen Wang, Xin-Man Hu, Wei Li, Yan Li, Yong Liu, Tong-Jiang Li, Chun-Zhi Ai. Computational prediction for the metabolism of human UDP-glucuronosyltransferase 1A1 substrates.
Computers in biology and medicine.
2022 10; 149(?):105959. doi:
10.1016/j.compbiomed.2022.105959. [PMID: 36063691] - Chang Liu, Zhenxing Wang, Qian Liu, Guangyao Wu, Chunhong Chu, Lanxin Li, Lei An, Shaofeng Duan. Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2022 Oct; 24(10):1975-1985. doi:
10.1007/s12094-022-02854-3. [PMID: 35666454] - Jisheng Li, Liping Zhu, Justin Stebbing, Ling Peng. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Journal of cancer research and therapeutics.
2022 Sep; 18(5):1436-1439. doi:
10.4103/jcrt.jcrt_433_22. [PMID: 36204894] - Abdelrahman Y Sherif, Gamaleldin I Harisa, Fars K Alanazi, Fahd A Nasr, Ali S Alqahtani. Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.
AAPS PharmSciTech.
2022 Jul; 23(6):183. doi:
10.1208/s12249-022-02332-7. [PMID: 35773422] - Wei Feng, Xi Chen, Shao-Xing Guan, Hong-Lian Ruan, Yan Huang, Hui-Zhen Zhang, Yun-Peng Yang, Wen-Feng Fang, Hong-Yun Zhao, Wei Zhuang, Shuang Xin, You-Hao Chen, Fei Wang, Yue Gao, Min Huang, Xue-Ding Wang, Li Zhang. Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.
Acta pharmacologica Sinica.
2022 Jul; 43(7):1857-1864. doi:
10.1038/s41401-021-00791-5. [PMID: 34737420] - Vichitra Behel, Anuradha Chougule, Vanita Noronha, Vijay Maruti Patil, Nandini Menon, Ajaykumar Singh, Sunil Chopade, Rajiv Kumar, Srushti Shah, Sucheta More, Shripad Dinanath Banavali, Pratik Chandrani, Kumar Prabhash. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Clinical lung cancer.
2022 Jul; 23(5):410-418. doi:
10.1016/j.cllc.2022.04.002. [PMID: 35649817] - Jang-Hee Oh, Woojune Hur, Na Li, Seong Jin Jo. Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes.
Experimental dermatology.
2022 06; 31(6):918-927. doi:
10.1111/exd.14538. [PMID: 35122447] - Wei-Ya Yan, Jian Cai, Jiang-Nan Wang, Yong-Sheng Gong, Xue-Bing Ding. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
Neoplasma.
2022 May; 69(3):648-656. doi:
10.4149/neo_2022_211103n1568. [PMID: 35330996] - Huaxin Zhou, Jia Fu, Qianqian Jia, Saisai Wang, Peida Liang, Yamin Wang, Yanni Lv, Shengli Han. Magnetic nanoparticles covalently immobilizing epidermal growth factor receptor by SNAP-Tag protein as a platform for drug discovery.
Talanta.
2022 Apr; 240(?):123204. doi:
10.1016/j.talanta.2021.123204. [PMID: 35026637] - Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo-Xun Wu, Jian-Ye Zhang, Xuansheng Ding. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression.
Molecular cancer.
2022 03; 21(1):77. doi:
10.1186/s12943-022-01547-3. [PMID: 35303882] - Guanru Wang, Yaru Xie, Xindi Qian, Xinyue Zhang, Yanqiang Shan, Minghui Zhang, Jie Li, Zhiwen Zhang, Yaping Li. Poly(maleic anhydride-alt-1-octadecene)-based bioadhesive nanovehicles improve oral bioavailability of poor water-soluble gefitinib.
Drug development and industrial pharmacy.
2022 Mar; 48(3):109-116. doi:
10.1080/03639045.2022.2098316. [PMID: 35786162] - Piao Zheng, Zhen Huang, Dong-Chang Tong, Qing Zhou, Sha Tian, Bo-Wei Chen, Di-Min Ning, Yin-Mei Guo, Wen-Hao Zhu, Yan Long, Wei Xiao, Zhe Deng, Yi-Chen Lei, Xue-Fei Tian. Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways.
World journal of gastrointestinal oncology.
2022 Feb; 14(2):450-477. doi:
10.4251/wjgo.v14.i2.450. [PMID: 35317323] - Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
2022 Feb; 527(?):1-10. doi:
10.1016/j.cca.2021.12.028. [PMID: 34999058] - Safna Hussan K P, Thekkekara D Babu, Pareeth C M, Greena Joshy, Deepu Mathew, M Shahin Thayyil. Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights.
Free radical research.
2022 Feb; 56(2):196-208. doi:
10.1080/10715762.2022.2065990. [PMID: 35514158] - Hongwei Han, Cong He, Xingyu Chen, Yuelin Luo, Minkai Yang, Zhongling Wen, Jiabao Hu, Faxiang Lin, Mi Han, Tongming Yin, Rongwu Yang, Hongyan Lin, Jinliang Qi, Yonghua Yang. Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
Bioorganic & medicinal chemistry letters.
2022 02; 57(?):128503. doi:
10.1016/j.bmcl.2021.128503. [PMID: 34922028] - Abdelrahman Y Sherif, Gamaleldin I Harisa, Fars K Alanazi, Fahd A Nasr, Ali S Alqahtani. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.
International journal of nanomedicine.
2022; 17(?):3287-3311. doi:
10.2147/ijn.s365974. [PMID: 35924261] - Yacine Tandjaoui-Lambiotte, Yanis Akrour, Aude Gibelin, Frederic Gonzalez, Annabelle Stoclin, Anne-Sophie Moreau, Paul Jaubert, Anne Oppenheimer, Boris Duchemann, Stéphane Gaudry. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Chest.
2022 01; 161(1):284-287. doi:
10.1016/j.chest.2021.06.079. [PMID: 34302842] - Yi Zhao, Caiming Zhang, Haibo Tang, Xiaomin Wu, Qiugan Qi. Mechanism of RNA circHIPK3 Involved in Resistance of Lung Cancer Cells to Gefitinib.
BioMed research international.
2022; 2022(?):4541918. doi:
10.1155/2022/4541918. [PMID: 35496045] - Jiying Wang, Zhaoying Sheng, Zhiyi Dong, Qiongya Wu, Yong Cai. The mechanism of radiotherapy for lung adenocarcinoma in promoting protein SIRT6-mediated deacetylation of RBBP8 to enhance the sensitivity of targeted therapy.
International journal of immunopathology and pharmacology.
2022 Jan; 36(?):3946320221130727. doi:
10.1177/03946320221130727. [PMID: 36172813] - Xiao Shen, Guorong Fan, Gaolin Liu, Fan Wang, Qi Li, Xinyan Liu, Hong Zhu, Ying Zhu, Jiguang Lu, Shuowen Wang. Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report.
Anti-cancer drugs.
2022 01; 33(1):e802-e807. doi:
10.1097/cad.0000000000001226. [PMID: 34459464] - Mei-Sa Wang, Qiu-Shuang Han, Zhi-Rong Jia, Chuan-Sheng Chen, Chen Qiao, Qian-Qian Liu, Ya-Meng Zhang, Kai-Wei Wang, Jie Wang, Kang Xiao, Xuan-Sheng Ding. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.
Acta pharmacologica Sinica.
2022 Jan; 43(1):167-176. doi:
10.1038/s41401-021-00638-z. [PMID: 33772142] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Ai-Lin Yang, Qi Wu, Zhong-Dong Hu, Shao-Ping Wang, Yu-Fan Tao, An-Mei Wang, Yi-Xuan Sun, Xiu-Lian Li, Long Dai, Jiayu Zhang. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Toxicology and applied pharmacology.
2021 11; 431(?):115739. doi:
10.1016/j.taap.2021.115739. [PMID: 34619160] - Qian Wang, Bing Lu, Yi Zhang, Jing Yu, Jie Guo, Qianchi Zhou, Hong Lv, Yifeng Sun. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Human cell.
2021 Nov; 34(6):1855-1865. doi:
10.1007/s13577-021-00582-4. [PMID: 34370268] - Xin Wang, Bingqing Deng, Meng Yu, Tao Zeng, Yuyu Chen, Jianqiang Hu, Qianqing Wu, Aiqing Li. Constructing a passive targeting and long retention therapeutic nanoplatform based on water-soluble, non-toxic and highly-stable core-shell poly(amino acid) nanocomplexes.
Biomaterials science.
2021 Oct; 9(21):7065-7075. doi:
10.1039/d1bm01246k. [PMID: 34590101] - Jui-Ling Hsu, Wohn-Jenn Leu, Nan-Shan Zhong, Jih-Hwa Guh. Autophagic Activation and Decrease of Plasma Membrane Cholesterol Contribute to Anticancer Activities in Non-Small Cell Lung Cancer.
Molecules (Basel, Switzerland).
2021 Oct; 26(19):. doi:
10.3390/molecules26195967. [PMID: 34641511] - Md Mohiuddin, Kazuo Kasahara. The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells.
Cancer genomics & proteomics.
2021 Sep; 18(5):661-673. doi:
10.21873/cgp.20288. [PMID: 34479918] - Qian Zeng, Han Gao, Longdan Zhang, Shouming Qin, Yongyao Gu, Quanfang Chen. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Anti-cancer drugs.
2021 09; 32(8):890-893. doi:
10.1097/cad.0000000000001094. [PMID: 34232939] - Zhijun Shen, Chen Chen, Jianhai Sun, Jingsong Huang, Shiguo Liu. The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
Journal of cancer research and clinical oncology.
2021 Aug; 147(8):2239-2248. doi:
10.1007/s00432-021-03640-4. [PMID: 34037837] - Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verzè, Amir Avan, Marcello Tiseo, Elisa Giovannetti. Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.
Cells.
2021 06; 10(6):. doi:
10.3390/cells10061520. [PMID: 34208765] - Robert S Plumb, Lee A Gethings, Adam King, Lauren G Mullin, Garth Maker, Robert Trengove, Ian D Wilson. Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: Application to gefitinib and metabolites in mouse plasma and urine.
Journal of pharmaceutical and biomedical analysis.
2021 Jun; 200(?):114076. doi:
10.1016/j.jpba.2021.114076. [PMID: 33892395] - Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Rosa Álvarez, Ana Herranz, María Sanjurjo. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Jun; 27(4):980-983. doi:
10.1177/1078155220949639. [PMID: 32799779] - Lu Liu, Qian Wang, Cen Xie, Ning Xi, Zitao Guo, Ming Li, Xiangyu Hou, Ningjie Xie, Mingming Sun, Jing Li, Xiaoyan Chen. Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
British journal of clinical pharmacology.
2021 04; 87(4):2098-2110. doi:
10.1111/bcp.14621. [PMID: 33098714] - Peng Xiao, Yu-Kang Liu, Wei Han, Yan Hu, Bo-You Zhang, Wen-Liang Liu. Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner.
Molecular cancer research : MCR.
2021 04; 19(4):726-738. doi:
10.1158/1541-7786.mcr-20-0541. [PMID: 33563765] - Billy J Molloy, Adam King, Lauren G Mullin, Lee A Gethings, Robert Riley, Robert S Plumb, Ian D Wilson. Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Apr; 51(4):434-446. doi:
10.1080/00498254.2020.1859643. [PMID: 33280466] - Rui Chen, Zijun Qian, Xin Xu, Congcong Zhang, Yongjie Niu, Zhixian Wang, Jianli Sun, Xiao Zhang, Yongchun Yu. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer.
Pharmacological research.
2021 03; 165(?):105442. doi:
10.1016/j.phrs.2021.105442. [PMID: 33497805] - Xun Gao, Yue Zhang, Tiantian Feng, Lei Cao, Wenjing Wu, Kunming Qin. Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Mar; 51(3):355-365. doi:
10.1080/00498254.2020.1859642. [PMID: 33269993] - Liyang Zhang, Xinyao Yi, Saisai Wang, Peida Liang, Huaxin Zhou, Jia Fu, Qianqian Jia, Jiapan Gao, Yanni Lv, Shengli Han. Construction of graphene quantum dots-decorated EGFR cell membrane chromatography for screening active components from Peucedanum praeruptorum Dunn.
Analytical and bioanalytical chemistry.
2021 Mar; 413(7):1917-1927. doi:
10.1007/s00216-021-03161-6. [PMID: 33506335] - Jérémy Barben, Valérie Quipourt, Jérémie Vovelle, Alain Putot, Patrick Manckoundia. Not COVID-19, Don't Overlook Pneumocystis in Patients on Gefitinib!.
Current oncology (Toronto, Ont.).
2021 02; 28(1):961-964. doi:
10.3390/curroncol28010094. [PMID: 33617512] - R B Verheijen, T T van Duijl, M M van den Heuvel, D Vessies, M Muller, J H Beijnen, J M Janssen, J H M Schellens, N Steeghs, D van den Broek, A D R Huitema. Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Cancer chemotherapy and pharmacology.
2021 02; 87(2):269-276. doi:
10.1007/s00280-021-04230-4. [PMID: 33484280] - Jia Xiong Ming, Zhao Cong Wang, Yi Huang, Hifumi Ohishi, Rong Ji Wu, Yan Shao, Hui Wang, Ming Yang Qin, Ze Liang Wu, Yi Yong Li, Shun Chang Zhou, Hui Chen, Hui Liu, Rong Xu. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib.
Journal of ethnopharmacology.
2021 Jan; 265(?):113302. doi:
10.1016/j.jep.2020.113302. [PMID: 32860893] - Liyan Wang, Tingting Zhao, Yunxiang Wang, Banglian Hu, Jianfei Tao, Jinshan Ke, Tingfei Wei, Guangbo Ge, Qiang Meng, Changyuan Wang, Qi Liu, Huijun Sun, Jingjing Wu, Yanwei Chen. In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity.
Current drug metabolism.
2021; 22(10):802-810. doi:
10.2174/1389200222666210902130319. [PMID: 34473615] - Ailing Xu, Haixia Yan, Tongliang Bu. Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC.
Pakistan journal of pharmaceutical sciences.
2021 Jan; 34(1(Special)):481-486. doi:
NULL. [PMID: 34275797] - Xiaoming Huang, Jingchun Sun, Jianli Sun. Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.
Current pharmaceutical biotechnology.
2021; 22(3):389-399. doi:
10.2174/1389201021999200819105209. [PMID: 32819223] - Hafiz A Makeen, Syam Mohan, Mohamed Ahmed Al-Kasim, Ibraheem M Attafi, Rayan A Ahmed, Nabeel Kashan Syed, Muhammad Hadi Sultan, Mohammed Al-Bratty, Hassan A Alhazmi, Mohammed M Safhi, Raisuddin Ali, M Intakhab Alam. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro.
Drug delivery.
2020 Dec; 27(1):622-631. doi:
10.1080/10717544.2020.1754526. [PMID: 32329374] - Sho Sakamoto, Kazuhiro Sato, Yuri Takita, Yuka Izumiya, Naho Kumagai, Kazuhisa Sudo, Yukiyasu Hasegawa, Hayato Yokota, Yumiko Akamine, Yuji Okuda, Mariko Asano, Masahide Takeda, Masaaki Sano, Masatomo Miura, Katsutoshi Nakayama. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
Investigational new drugs.
2020 12; 38(6):1687-1695. doi:
10.1007/s10637-020-00946-x. [PMID: 32436059] - Jianchun Duan, JiaChen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Jiefei Han, Di Wang, Yanhua Tian, Zhenlin Yang, Li Zhang, Shaokun Chuai, Junyi Ye, Guanshan Zhu, Junhui Zhao, Yi-Long Wu, Jie Wang. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020 12; 15(12):1857-1870. doi:
10.1016/j.jtho.2020.08.020. [PMID: 32916309] - Liangqin Wan, Yalei Wang, Yibo Tang, Yan Tan, Fang He, Yali Zhang, Ke Yang, Ziwei Chen, Chenchen Song, Ruoxi Gu, Ce Zhang, Xu Wang, Peng Wei, Tonghua Liu, Miao Jiang, Qian Hua. Gefitinib-Induced Cutaneous Toxicities in Brown Norway Rats Are Associated with Macrophage Infiltration.
Inflammation.
2020 Dec; 43(6):2137-2146. doi:
10.1007/s10753-020-01281-2. [PMID: 33025329] - Shuiping Liu, Qiujie Li, Guohua Li, Qin Zhang, Lvjia Zhuo, Xuemeng Han, Mingming Zhang, Xiaying Chen, Ting Pan, Lili Yan, Ting Jin, Jianjun Wang, Qun Lv, Xinbing Sui, Tian Xie. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene.
Cell death & disease.
2020 11; 11(11):969. doi:
10.1038/s41419-020-03148-8. [PMID: 33177491] - Yi-Wen Chang, Chia-Lang Hsu, Cheng-Wei Tang, Xiang-Jun Chen, Hsuan-Cheng Huang, Hsueh-Fen Juan. Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network.
Molecular & cellular proteomics : MCP.
2020 11; 19(11):1805-1825. doi:
10.1074/mcp.ra120.002219. [PMID: 32788343] - Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Journal of medicinal chemistry.
2020 10; 63(19):10726-10741. doi:
10.1021/acs.jmedchem.0c00507. [PMID: 32432477] - Zirui Wan, Lifang Guo, Pengfei Li, Zhixia Zhao, Benshan Xu, Lulu Ren, Yan Yan, He Liu, Yiwen Zhang, Lihong Liu. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
Journal of clinical pharmacy and therapeutics.
2020 Oct; 45(5):1159-1167. doi:
10.1111/jcpt.13168. [PMID: 32562509] - Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Cancer chemotherapy and pharmacology.
2020 10; 86(4):517-525. doi:
10.1007/s00280-020-04136-7. [PMID: 32948919] - Chi Pan, Huijie Duan, Yinan Wu, Chunpeng Zhu, Chenghao Yi, Yin Duan, Demin Lu, Cheng Guo, Deqi Wu, Yanyan Wang, Xianhua Fu, Jing Xu, Yiding Chen, Meng Luo, Wei Tian, Tao Pan, Wenhong Xu, Suzhan Zhang, Jianjin Huang. Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
International journal of oncology.
2020 10; 57(4):939-955. doi:
10.3892/ijo.2020.5103. [PMID: 32945394] - Nazafarin Satari, Somayeh Taymouri, Jaleh Varshosaz, Mahboubeh Rostami, Mina Mirian. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Drug development and industrial pharmacy.
2020 Aug; 46(8):1265-1277. doi:
10.1080/03639045.2020.1788063. [PMID: 32594775] - Yujie Liu, Hao Zeng, Ke Wang, Yalun Li, Panwen Tian, Weimin Li. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Lung cancer (Amsterdam, Netherlands).
2020 08; 146(?):355-357. doi:
10.1016/j.lungcan.2020.06.004. [PMID: 32553555] - Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura. Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.
Journal of clinical pharmacy and therapeutics.
2020 Aug; 45(4):652-659. doi:
10.1111/jcpt.13173. [PMID: 32402096] - Wee Kiat Tan, Alyssa Rui Yi Tan, Punitha Sivanandam, Ernest Jing Hui Goh, Ze Ping Yap, Nur Fazilah Saburulla, Karl Austin-Muttitt, Jonathan G L Mullins, Aik Jiang Lau. In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
The Journal of pharmacology and experimental therapeutics.
2020 08; 374(2):295-307. doi:
10.1124/jpet.120.265249. [PMID: 32393528] - Qingda Zhao, Kai Sun, Xuemei Lei, Le Cai. A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Medicine.
2020 Jul; 99(31):e21490. doi:
10.1097/md.0000000000021490. [PMID: 32756179] - Nan Chen, Gaofeng Li, Heng Li, Xudong Xiang, Gang Guo, Qianli Ma, Ying Zhang. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
Cellular and molecular biology (Noisy-le-Grand, France).
2020 Jul; 66(5):208-213. doi:
10.14715/cmb/2020.66.5.35. [PMID: 33040838] - Ali Alhoshani, Fawaz E Alanazi, Moureq R Alotaibi, Mohamed W Attwa, Adnan A Kadi, Abdullah Aldhfyan, Sabah Akhtar, Shireen Hourani, Abdelali Agouni, Asad Zeidan, Hesham M Korashy. EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and in Vitro Rat Studies.
Chemical research in toxicology.
2020 07; 33(7):1719-1728. doi:
10.1021/acs.chemrestox.0c00005. [PMID: 32370496] - Can Zhao, Huifeng Hao, Haiyu Zhao, Wei Ren, Yanna Jiao, Guo An, Hong Sun, Shuyan Han, Pingping Li. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
Journal of ethnopharmacology.
2020 Jun; 255(?):112770. doi:
10.1016/j.jep.2020.112770. [PMID: 32205262] - Susana Torres, Álvaro González, Alberto Jacobo Cunquero Tomas, Silvia Calabuig Fariñas, Macarena Ferrero, Danielle Mirda, Rafael Sirera, Eloisa Jantus-Lewintre, Carlos Camps. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Expert review of molecular diagnostics.
2020 06; 20(6):575-582. doi:
10.1080/14737159.2020.1724094. [PMID: 32011193] - Yujia Xu, Kun Zeng, Xiaoge Wang, Jieyu Zhang, Biyin Cao, Zubin Zhang, Chunhua Qiao, Xiaofeng Xu, Qi Wang, Yuanying Zeng, Xinliang Mao. Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway.
Bioscience trends.
2020 May; 14(2):96-103. doi:
10.5582/bst.2019.01302. [PMID: 32173687] - Fang Zheng, Jing Li, ChangJu Ma, XiaoJuan Tang, Qing Tang, JingJing Wu, XiaoSu Chai, Jianhui Xie, Xiao-Bo Yang, Swei Sunny Hann. Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer.
Journal of cellular and molecular medicine.
2020 05; 24(10):5578-5592. doi:
10.1111/jcmm.15214. [PMID: 32248643] - Marzia Del Re, Iacopo Petrini, Francesca Mazzoni, Simona Valleggi, Giulia Gianfilippo, Daniele Pozzessere, Antonio Chella, Stefania Crucitta, Eleonora Rofi, Giuliana Restante, Mario Miccoli, Marina Chiara Garassino, Romano Danesi. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Clinical lung cancer.
2020 05; 21(3):232-237. doi:
10.1016/j.cllc.2019.10.003. [PMID: 31735523] - Jean-Luc Raoul, Julien Edeline, Marine Gilabert, Hélène Senellart, Jean-Sébastien Frenel. [Proton pump inhibitors and cancers: A hazardous association?].
Bulletin du cancer.
2020 Apr; 107(4):458-464. doi:
10.1016/j.bulcan.2019.12.009. [PMID: 32057465] - Xin Li, Minghui Liu, Hongbing Zhang, Hongyu Liu, Jun Chen. Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Thoracic cancer.
2020 03; 11(3):819-826. doi:
10.1111/1759-7714.13303. [PMID: 31918452] - Ha-Na Oh, Mee-Hyun Lee, Eunae Kim, Ah-Won Kwak, Goo Yoon, Seung-Sik Cho, Kangdong Liu, Jung-Il Chae, Jung-Hyun Shim. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
Biomolecules.
2020 02; 10(2):. doi:
10.3390/biom10020297. [PMID: 32070026] - Guofeng Ma, Ye Liang, Yuanbin Chen, Liping Wang, Dan Li, Zhijuan Liang, Xiao Wang, Dongxu Tian, Xuecheng Yang, Haitao Niu. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
Molecular cancer research : MCR.
2020 02; 18(2):324-339. doi:
10.1158/1541-7786.mcr-19-0517. [PMID: 31672701] - Ha-Na Oh, Mee-Hyun Lee, Eunae Kim, Ah-Won Kwak, Ji-Hye Seo, Goo Yoon, Seung-Sik Cho, Joon-Seok Choi, Sang-Myeong Lee, Kang-Seok Seo, Jung-Il Chae, Jung-Hyun Shim. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Phytotherapy research : PTR.
2020 Feb; 34(2):388-400. doi:
10.1002/ptr.6530. [PMID: 31698509] - Teresa Delgado-Goñi, Teresa Casals Galobart, Slawomir Wantuch, Deimante Normantaite, Martin O Leach, Steven R Whittaker, Mounia Beloueche-Babari. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
British journal of cancer.
2020 01; 122(1):72-81. doi:
10.1038/s41416-019-0628-x. [PMID: 31819183]
